Autor: Abhishek Aich
This year’s European Society for Medical Oncology (ESMO) Congress 2024 was a very successful event for BIOTYPE. The BIOTYPE team met personally with key figures from European and American top clinics and major pharmaceutical companies. As an overview of the event, 34000 participants from 149 countries gathered in the beautiful city of Barcelona to connect with leading minds in oncology, to explore groundbreaking research and to gain cutting-edge insights into the rapidly evolving landscape of cancer diagnostics. Here are some relevant updates for SNRT members.
Radioligand Therapy (RLT)Clinical Efficacy in Prostate CancerSilke Gillessen and Dr. Ken Herrmann highlighted the growing role of radioligand therapy in prostate cancer, specifically through the use of 177Lu-PSMA-617. The VISION trial demonstrated significant improvements in radiographic progression-free survival (rPFS) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC). Thus, for patients with mCRPC after docetaxel and an ARPI, 177Lu-PSMA was announced to be Standard of Care. Newer developments, such as alpha emitters like 225Ac-PSMA, show promise for enhancing therapeutic efficacy while addressing limitations in disease control. Patient Selection and ImagingAdvances in imaging, such as 68Ga-PSMA PET and FDG PET, are improving patient selection by identifying optimal candidates and avoiding those with discordant lesions.
These imaging tools ensure targeted delivery of RLT, minimizing off-target. Pipeline ExpansionNumerous radioligands, including 227Th-PSMA-TTC and 131I-PSMA-1095, are currently in clinical trials, showcasing the diversification of theranostic applications. Antibody-Drug Conjugates (ADCs) Dr. Aditya Bardia emphasized parallels in targeted therapy development with ADCs, such as Trastuzumab Deruxtecan and Sacituzumab Govitecan, which demonstrate robust clinical benefits across tumor types like HER2-low breast cancer and mTNBC respectively. These successes validate the potential for theranostics to expand into broader oncological applications.
Additionally, he talked about the role of 90Y-FF-21101 Monoclonal Antibody in Solid Tumors and over 100 similar ADCs in clinical trials targeting a wide array of antigens across tumor types. Innovative DirectionsIntegration of theranostics with other modalities, including immunotherapy and PARP inhibitors, is being explored to optimize therapeutic outcomes. Reasonable combinations and biomarker-driven approaches are pivotal to advancing the field.Thus, all the presentations showed a transformative phase for theranostics, with enhanced targeting strategies, novel isotopes, and broadened applications paving the way for a new standard in personalized oncology care.
Speakers: Dr. Silke Gillessen (Oncology Institute of Southern Switzerland), Dr. Ken Herrmann (Universitätsmedizin Essen), Dr. Aditya Bardia (UCLA).